Innoviva (INVA) FCF Payout Ratio Growth (1y) (2015 - 2022)
Powered by 
Analysis
Innoviva (INVA) FCF Payout Ratio Growth (1y) (2015 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -31.89% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 107.33% |
| Jun 30, 2022 | -49.30% |
| Mar 31, 2022 | -73.79% |
| Jun 30, 2021 | 56.46% |
| Mar 31, 2021 | 17.60% |
| Jun 30, 2020 | 286,696.58% |
| Mar 31, 2020 | 206,097.86% |
| Sep 30, 2019 | 455.07% |
| Jun 30, 2019 | -99.66% |
| Mar 31, 2019 | -94.21% |
| Dec 31, 2018 | 1,660.02% |
| Sep 30, 2018 | 3,589.58% |
| Jun 30, 2018 | 785.21% |
| Mar 31, 2018 | -25.29% |
| Dec 31, 2017 | -8.62% |
| Sep 30, 2017 | -65.60% |
| Jun 30, 2017 | -82.26% |
| Mar 31, 2017 | -97.57% |
| Dec 31, 2016 | -88.58% |
| Sep 30, 2016 | -99.98% |